ASCO GU 2019 Bladder Cancer

Viewing 1-20 of 25 articles

ASCO GU 2019: PIVOT-02 Study of NKTR-214 with Nivolumab in Metastatic Urothelial Carcinoma

ASCO GU 2019: Gemcitabine-Carboplatin versus Gemcitabine-Oxaliplatin In Cisplatin Un-Fit Advanced Urothelial Carcinoma: Randomized Phase II Study-COACH Study

ASCO GU 2019: CheckMate 9UT - Nivolumab or Nivo Plus BMS-986205 with or without Intravesical Bacillus Calmette-Guerin in BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer

ASCO GU 2019: POTOMAC Study - Durvalumab and BCG versus BCG Alone in High-risk, BCG-Naïve Non Muscle-Invasive Bladder Cancer

ASCO GU 2019: Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

ASCO GU 2019: Ramucirumab Exposure-Response Relationship in RANGE: Trial in Advanced Platinum-Refractory Urothelial Carcinoma

ASCO GU 2019: Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma - AMBASSADOR versus Observation

ASCO GU 2019: A Phase III, Randomized, Open-label, Multicenter, Global Study of Durvalumab and BCG versus BCG Alone in High-risk, BCG-naïve Non-muscle-invasive Bladder Cancer Patients - POTOMAC

ASCO GU 2019: ATLAS: A Phase II Open-Label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

ASCO GU 2019: Perioperative Immunotherapy in Urothelial Carcinoma: State of Existing Evidence

ASCO GU 2019: Updated Results of Keynote 057: Pembrolizumab for Patients with High-risk Nonmuscle Invasive Bladder Cancer Unresponsive to BCG

ASCO GU 2019: Randomized Phase III Trial of Adjuvant Sequential Chemotherapy plus Radiotherapy versus Adjuvant Radiotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy: Urothelial Carcinoma Subgroup Analysis.

ASCO GU 2019: Sacituzumab Govitecan (IMMU-132) in Patients with Previously Treated Metastatic Urothelial Cancer

ASCO GU 2019: Challenges of Therapy in Upper-Tract Urothelial Carcinoma

ASCO GU 2019: Trimodality Therapy is the Best Option for Muscle-Invasive Bladder Cancer

ASCO GU 2019: Interim Analysis of Ibrutinib Plus Paclitaxel for Patients with Metastatic Urothelial Carcinoma Previously Treated with Platinum-Based Chemotherapy

ASCO GU 2019: Fierce-21: Phase II Study of Vofatamab, a Selective Inhibitor of FGFR3, as Salvage Therapy in Metastatic Urothelial Carcinoma

ASCO GU 2019: Radical Cystectomy is the Best Option for Muscle-Invasive Bladder Cancer

ASCO GU 2019: Multimodality Treatment in Challenging Cases of Urothelial Carcinoma: Case Panel Discussion

ASCO GU 2019: Genomic Insights and Biomarkers for Treatment Selection in Muscle-Invasive and Non-Muscle-Invasive Bladder Cancer

1
2

E-Newsletters

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.